

Area Drugs and Therapeutics Committee Meeting MinutesWednesday 15th November 2023 at 10am-11.30am

Microsoft Teams Meeting

Present:

Mehrdad Malekian (Chair)	Victoria Gemmell (minutes)
Tyra Smyth	Mark Kirk
Kirsty Macfarlane	Gail Richardson
Penny Brankin	Carol McGoff
Christine Gilmour	Emma Harris
Julie Russell (observer)	Craig Thurtell (observer)
David Semple (from 10:30)	

1. Apologies: Colin Angus, Kelly Baillie**2. Declaration of Interest****Nil declared**

Item	Notes	Action
3	Minutes/Actions from the last meeting	
4	Matters Arising a) Ogluo-update This was discussed and comments include Clarify target audience Discrepancy between target audience age noted in document and age restrictions within the license Further information requested around what qualifies as severe distress and how this is measured and documented Further clarification was sought on implications of introduction due to training needs, who would be expected to prescribe, and supply routes. Page 2, final paragraph, wording unclear (Ogluo as Glucagen) Under dose and administration-add- <i>subcutaneous injection into the lower abdomen, outer thigh or outer upper arm.</i> Add "hours" to <i>monitored for 6-8 total</i> b) IV Fluids-update awaited Expected December c) Deprescribing Guideline-update awaited Expected December	MM
5	SMC Advice-CONFIDENTIAL	

Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website **after 10.00 am on Monday 11 December 2023.**

Full Submissions

- trastuzumab deruxtecan (Enhertu) Daiichi Sankyo UK Ltd SMC2608 **Accepted with PAS**
Await advice from WoSCAN
- nivolumab concentrate for solution for infusion (Opdivo) Bristol Myers Squibb SMC2619 **Accepted with PAS**
Await advice from WoSCAN
- deucravacitinib film-coated tablets (Sotyktu) Bristol Myers Squibb SMC2581 **Accepted Restricted with PAS**
Refer to DERMATOLOGY for advice

Reassessment

- cemiplimab (Libtayo) Regeneron UK Limited SMC2584 **Accepted with PAS**
Await advice from WoSCAN

Abbreviated Submissions

- ciplaglusidase alfa powder for concentrate for solution for infusion (Pombiliti) Amicus Therapeutics SMC2606 **Accepted with PAS**
AVAILABLE IN LINE WITH NATIONAL GUIDANCE
- bimekizumab 160mg solution for injection in pre-filled syringe/ prefilled pen (Bimzelx) UCB Pharma Ltd SMC2616 **Accepted with PAS**
Refer to RHEUMATOLOGY for advice
- degarelix injection(Firmagon) Ferring Pharmaceuticals Ltd SMC2625 **Accepted with PAS**
Await advice from WoSCAN

Non Submissions

- amivantamab (Rybrevant) Janssen-Cilag Ltd SMC2638
- lumasiran (Oxlumo) Alnylam UK Ltd SMC2639
- osilodrostat (Isturisa) Recordati Rare Diseases UK Ltd SMC2640

FOR NOTING

Amended Advice

regorafenib film-coated tablets (Stivarga®) Bayer Plc. SMC2562

FOR NOTING

mercaptamine gastro-resistant hard capsules (Procysbi®) Chiesi SMC2571

FOR NOTING

pegunigalsidase alfa concentrate for solution for infusion (Elfabrio®) Chiesi Ltd. SMC2591

FOR NOTING

FOR INFORMATION

Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.

Update for health boards: lorlatinib film-coated tablets (Lorviqua®) Pfizer Limited

SMC2239

FOR NOTING

	<p><u>Paediatric Licence Extensions</u> FOR NOTING</p> <p><u>Outwith remit decisions (based on criterion 14)</u> FOR NOTING</p>	
6.	<p><u>SMC follow up</u> CONFIDENTIAL</p> <p>KMAC updated the committee on plans for prescribing of migraine medicines approved by SMC. Currently, NHSL patients attend specialist clinics in GGC and discussions are ongoing about how the Boards link in together.</p> <p>Feedback was given on SMC2534 risankizumab, SMC2605 bimekizumab and SMC2578 avacopan. Submissions to ADTC regarding the implementation of the use of these in NHS Lanarkshire are expected in due course.</p> <p>Feedback is awaited on a number of other items.</p>	VG
7.	<p><u>Lanarkshire Formulary</u></p> <p>Mental Health Section Use of Sleepio app noted, KMAC to check this is approved by the Apps Group. Other changes were summarized and accepted. It was noted that MH teams were helpful contributors to the process and thanks was given for their input</p> <p>Treatment of Addiction Section The addition of a note regarding strength of diazepam that may be prescribed was discussed. To be discussed further with Addictions Team. Change to naloxone nasal products were discussed. This was accepted. All other changes to the section were accepted. Due to changes in Scottish Drug Tariff, some updates were proposed. These were accepted.</p>	KM VG
8.	<p><u>Clinical Protocols</u></p> <p>(a) Massive PE Guidance-Update To be formatted and references, collaborators etc to be added. Second box-iv should be capitals. Also need to state which iv fluid is recommended for infusion It would be helpful to clarify that the decision to thrombolysed will be made by a senior clinician. Final copy to be returned for final discussion</p> <p>(b) Items which should not be routinely prescribed The document was welcomed by the committee. The purpose is to raise awareness with patients and clinicians about items which have low therapeutic value but are often requested/prescribed There was helpful discussion around implementation and consideration of unintended consequences e.g. lidocaine plasters, and the potential impact on prescribing of other</p>	MM VG

	<p>medicines. It was suggested that the Pain group and physio teams may be helpful to link with here Consider exceptions for palliative care The document has been shared with a variety of stakeholders and will be returned once feedback has been received.</p> <p>(c) NHSL HF Guideline update Update to previous guideline to reflect changes in SMC restriction To be formatted onto current template-this would cover other questions such as list of collaborators, who the guideline is aimed etc. Uses too many abbreviations/technical terms.</p> <p>(d) Orbital Cellulitis Guideline NHSL It was discussed that further guidance on follow up arrangements post discharge would be helpful Choice of antimicrobial-clarify if these are combinations or options</p>	<p>MM</p> <p>VG</p>
9.	<p><u>ADTC New Medicines Decisions</u></p> <p>These were noted.</p>	<p>CMcG</p>
10.	<p><u>Unlicensed Medicines</u></p> <p>(a) Rituximab Blanket Approval ANCA Vasculitis This was discussed and supported by the committee</p>	
11.	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update KMAC fed back that as part of yellow card week, a representative from the Yellow Card team did an awareness session with the pharmacy prescribing team. Suggestion to move link to yellow card reporting website to somewhere more intuitive, possibly to the beginning of the formulary section</p>	
12.	<p><u>Regional Cancer Advisory Network</u> Nil</p>	
13.	<p><u>Patient Safety Alerts</u> Nil</p>	
14.	<p><u>Lay member related items</u> NIL</p>	
13.	<p><u>Correspondence</u></p> <p>(a) <u>ADTC Collaborative</u></p>	

	VG gave feedback on the recent meeting.	
14.	Pharmacy & NMAHP Prescribing Governance Nil	
15.	<u>AOCB</u> Meeting dates for 2024 will be shared Thanks was given to CMcG for her contribution to the committee and best wishes for her future	
16.	<u>Date of next meeting</u> Wednesday 20 th December 2023 10am – 11.30am MS TEAMS	